Literature DB >> 30539058

A report of human papilloma virus-16 associated vaginal carcinoma after thirty-two years of successful radiation therapy for cervical cancer.

Gazal Jain1, Sasidharanpillai Sabeena2, Akhila Vasudeva1, Anjali Mundkur1, Srilatha Parampalli Srinivas3, G Arunkumar2, Pratap Kumar1.   

Abstract

Once the recommended 5-year recurrence-free follow-up is achieved for cervical cancers regular annual pelvic examination is mandatory. The main aim of presenting this short report is to emphasize the difficulties in the collection and interpretation of cytology samples from stenosed cervix or vault after pelvic irradiation. Radiotherapy can induce changes in the cellular morphology which may persist for many years. A 64-year old post-menopausal lady who had received radiation therapy 32 years back for cervical carcinoma stage IIb presented to the Gynecology outpatient department with vaginal spotting. Even though the patient was under regular follow-up for the initial 2 years, she was lost to further follow-ups. The patient was symptom-free except for one episode of spotting in August 2016 and the histopathological examination of the vault smear had ruled out malignancy. However, 1 month later she again presented with spotting and pelvic examination revealed a warty growth at the lateral vaginal wall. The tissue excision biopsy was tested positive for HPV-16 DNA and the histopathology confirmed vaginal squamous cell carcinoma. The association of human papilloma virus (HPV) in cervical cancers was well established and these patients manifest a higher risk of HPV-induced vaginal cancers. HPV DNA testing during follow-up may facilitate early recognition of HPV-related lower genital tract cancers.

Entities:  

Keywords:  Cervical cancer; Human papilloma virus (HPV); Recurrence; Vaginal cancer

Year:  2018        PMID: 30539058      PMCID: PMC6261890          DOI: 10.1007/s13337-018-0479-8

Source DB:  PubMed          Journal:  Virusdisease        ISSN: 2347-3584


  16 in total

Review 1.  A common clinical dilemma: Management of abnormal vaginal cytology and human papillomavirus test results.

Authors:  Michelle J Khan; L Stewart Massad; Walter Kinney; Michael A Gold; E J Mayeaux; Teresa M Darragh; Philip E Castle; David Chelmow; Herschel W Lawson; Warner K Huh
Journal:  Gynecol Oncol       Date:  2016-02-22       Impact factor: 5.482

2.  Persistence of HPV after radio-chemotherapy in locally advanced cervical cancer.

Authors:  Gianna Badaracco; Antonella Savarese; Adriana Micheli; Consuelo Rizzo; Francesca Paolini; Mariantonia Carosi; Giuseppe Cutillo; Enrico Vizza; Giorgio Arcangeli; Aldo Venuti
Journal:  Oncol Rep       Date:  2010-04       Impact factor: 3.906

3.  Follow-up for women after treatment for cervical cancer.

Authors:  L Elit; A W Fyles; T K Oliver; M C Devries-Aboud; M Fung-Kee-Fung
Journal:  Curr Oncol       Date:  2010-06       Impact factor: 3.677

4.  A population-based study of squamous cell vaginal cancer: HPV and cofactors.

Authors:  Janet R Daling; Margaret M Madeleine; Stephen M Schwartz; Katherine A Shera; Joseph J Carter; Barbara McKnight; Peggy L Porter; Denise A Galloway; James K McDougall; Hisham Tamimi
Journal:  Gynecol Oncol       Date:  2002-02       Impact factor: 5.482

5.  The association of pre-treatment HPV subtypes with recurrence of VIN.

Authors:  Giorgio Bogani; Fabio Martinelli; Antonino Ditto; Mauro Signorelli; Francesca Taverna; Claudia Lombardo; Valentina Chiappa; Umberto Leone Roberti Maggiore; Dario Recalcati; Cono Scaffa; Stefania Perotto; Ilaria Sabatucci; Alice Indini; Domenica Lorusso; Francesco Raspagliesi
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2017-02-01       Impact factor: 2.435

6.  Persistent human papillomavirus DNA is associated with local recurrence after radiotherapy of uterine cervical cancer.

Authors:  Yong Jung Song; Joo-Young Kim; Su-Kyoung Lee; Hyun-Sun Lim; Myong Cheol Lim; Sang-Soo Seo; Sokbom Kang; Dong Ock Lee; Sang-Yoon Park
Journal:  Int J Cancer       Date:  2010-12-08       Impact factor: 7.396

7.  Second cancers among 104,760 survivors of cervical cancer: evaluation of long-term risk.

Authors:  Anil K Chaturvedi; Eric A Engels; Ethel S Gilbert; Bingshu E Chen; Hans Storm; Charles F Lynch; Per Hall; Froydis Langmark; Eero Pukkala; Magnus Kaijser; Michael Andersson; Sophie D Fosså; Heikki Joensuu; John D Boice; Ruth A Kleinerman; Lois B Travis
Journal:  J Natl Cancer Inst       Date:  2007-10-30       Impact factor: 13.506

8.  Cervicovaginal cytology in patients undergoing pelvic radiotherapy using the Focalpoint system: results from the RODEO study.

Authors:  Maíra Degiovani Stein; José Humberto T G Fregnani; Cristovam Scapulatempo-Neto; Adhemar Longatto-Filho
Journal:  Diagn Pathol       Date:  2015-01-16       Impact factor: 2.644

9.  Immunosuppression facilitates the reactivation of latent papillomavirus infections.

Authors:  G A Maglennon; P B McIntosh; J Doorbar
Journal:  J Virol       Date:  2013-10-30       Impact factor: 5.103

10.  Detection of Human Papillomavirus Infection in Patients with Vaginal Intraepithelial Neoplasia.

Authors:  Cristina Lamos; Charlotte Mihaljevic; Sebastian Aulmann; Thomas Bruckner; Christoph Domschke; Markus Wallwiener; Carmen Paringer; Herbert Fluhr; Sarah Schott; Christine Dinkic; Janina Brucker; Michael Golatta; Lisa Gensthaler; Michael Eichbaum; Christof Sohn; Joachim Rom
Journal:  PLoS One       Date:  2016-12-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.